Neisseria gonorrhoeae Infections - Pipeline Review, H2 2016

  • ID: 3821635
  • Drug Pipelines
  • 98 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Allergan Plc
  • BioDiem Ltd
  • Biolytics Pharma
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck & Co., Inc.
  • MORE
Neisseria gonorrhoeae Infections - Pipeline Review, H2 2016

Summary

‘Neisseria gonorrhoeae Infections - Pipeline Review, H2 2016’, provides an overview of the Neisseria gonorrhoeae Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neisseria gonorrhoeae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neisseria gonorrhoeae Infections and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neisseria gonorrhoeae Infections
- The report reviews pipeline therapeutics for Neisseria gonorrhoeae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Neisseria gonorrhoeae Infections therapeutics and enlists all their major and minor projects
- The report assesses Neisseria gonorrhoeae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neisseria gonorrhoeae Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Neisseria gonorrhoeae Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neisseria gonorrhoeae Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan Plc
  • BioDiem Ltd
  • Biolytics Pharma
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck & Co., Inc.
  • MORE
List of Figures

Introduction

Report Coverage

Neisseria gonorrhoeae Infections Overview

Therapeutics Development

Pipeline Products for Neisseria gonorrhoeae Infections - Overview

Pipeline Products for Neisseria gonorrhoeae Infections - Comparative Analysis

Neisseria gonorrhoeae Infections - Therapeutics under Development by Companies

Neisseria gonorrhoeae Infections - Therapeutics under Investigation by Universities/Institutes

Neisseria gonorrhoeae Infections - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Neisseria gonorrhoeae Infections - Products under Development by Companies

Neisseria gonorrhoeae Infections - Products under Investigation by Universities/Institutes

Neisseria gonorrhoeae Infections - Companies Involved in Therapeutics Development

Allergan Plc

BioDiem Ltd

Biolytics Pharma

Debiopharm International SA

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

Merck & Co., Inc.

Paratek Pharmaceuticals, Inc.

Recce Pty Ltd

Redx Pharma Plc

Sarepta Therapeutics, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Neisseria gonorrhoeae Infections - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BDM-I - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Neisseria Gonorrhoeae Infection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dalbavancin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Debio-1453 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

edodekin alfa SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gepotidacin mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neisseria gonorrhoeae (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neisseria gonorrhoeae vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omadacycline tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Neisseria gonorrhoeae Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SM-295291 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SM-369926 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target Bacterial Cell Wall for Gonorrhoea and Tuberculosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DNA Gyrase for Neisseria Gonorrhoeae Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PBP2 for Neisseria Gonorrhoeae Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Tubulin for Oncology and Neisseria Gonorrhoeae Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VT-12008911 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neisseria gonorrhoeae Infections - Dormant Projects

Neisseria gonorrhoeae Infections - Discontinued Products

Neisseria gonorrhoeae Infections - Product Development Milestones

Featured News & Press Releases

Dec 22, 2015: Cempra Enters Into a CRADA With the NIAID and Expands the Phase 3 Solithromycin Clinical Trial in Urogenital Gonorrhea to Include Additional Female Patients and Adolescents

Sep 10, 2015: Cempra to Present Data From Antibiotic Drug Solithromycin at ICAAC/ICC 2015 Meeting

Nov 19, 2014: Cempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies

Sep 09, 2014: Durata Therapeutics Presented Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection

Apr 26, 2013: Cempra To Present Data On Solithromycin's Potential Against Urogenital Infections And Multidrug-Resistant Pathogens At ECCMID

Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I

Mar 31, 2012: Cempra's Solithromycin Demonstrates In Vitro Activity Against Antibiotic-Resistant Neisseria Gonorrhoeae Isolates

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Neisseria gonorrhoeae Infections, H2 2016

Number of Products under Development for Neisseria gonorrhoeae Infections - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Neisseria gonorrhoeae Infections - Pipeline by Allergan Plc, H2 2016

Neisseria gonorrhoeae Infections - Pipeline by BioDiem Ltd, H2 2016

Neisseria gonorrhoeae Infections - Pipeline by Biolytics Pharma, H2 2016

Neisseria gonorrhoeae Infections - Pipeline by Debiopharm International SA , H2 2016

Neisseria gonorrhoeae Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016

Neisseria gonorrhoeae Infections - Pipeline by GlaxoSmithKline Plc, H2 2016

Neisseria gonorrhoeae Infections - Pipeline by Merck & Co., Inc., H2 2016

Neisseria gonorrhoeae Infections - Pipeline by Paratek Pharmaceuticals, Inc., H2 2016

Neisseria gonorrhoeae Infections - Pipeline by Recce Pty Ltd, H2 2016

Neisseria gonorrhoeae Infections - Pipeline by Redx Pharma Plc, H2 2016

Neisseria gonorrhoeae Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2016

Neisseria gonorrhoeae Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Neisseria gonorrhoeae Infections - Dormant Projects, H2 2016

Neisseria gonorrhoeae Infections - Discontinued Products, H2 2016 87List of Figures

Number of Products under Development for Neisseria gonorrhoeae Infections, H2 2016

Number of Products under Development for Neisseria gonorrhoeae Infections - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Allergan Plc
BioDiem Ltd
Biolytics Pharma
Debiopharm International SA
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Merck & Co., Inc.
Paratek Pharmaceuticals, Inc.
Recce Pty Ltd
Redx Pharma Plc
Sarepta Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll